EUVIMEDОткрийте EUVIMED
Open access · CC BY-NC-ND 4.0

Metabolism‐focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer

Takashi Furusawa, Renzo Cavero, Yue Liu, Haojian Li, Xia Xu, Thorkell Andresson, William Reinhold, Olivia White, Myriem Boufraqech, Thomas J Meyer, Oliver Hartmann, Markus E Diefenbacher and 2 more

Molecular Carcinogenesis · 2024-06 · 63 (6) · 1024-1037

DOI: 10.1002/mc.23705 ↗

At a glance

Journal article in Molecular Carcinogenesis, published online on 2024-02-27. Written by Takashi Furusawa and 13 co-authors. Institution: Developmental Therapeutics Branch, NCI Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, Unit…. Major MEDLINE topics: Drug Resistance, Neoplasm, Lung Neoplasms, Monocarboxylic Acid Transporters, Poly(ADP-ribose) Polymerase Inhibitors. Cited 9 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Intramural NIH HHS, NCI NIH HHS, NCI center for cancer research.

РезюмеSubjectsБиблиографски данниCiteRelated studies

Abstract (original language)

Homologous recombination (HR) and poly ADP‐ribosylation are partially redundant pathways for the repair of DNA damage in normal and cancer cells. In cell lines that are deficient in HR, inhibition of poly (ADP‐ribose) polymerase (poly (ADP‐ribose) polymerase [PARP]1/2) is a proven target with several PARP inhibitors (PARPis) currently in clinical use. Resistance to PARPi often develops, usually involving genetic alterations in DNA repair signaling cascades, but also metabolic rewiring particularly in HR‐proficient cells. We surmised that alterations in metabolic pathways by cancer drugs such as Olaparib might be involved in the development of resistance to drug therapy. To test this hypothesis, we conducted a metabolism‐focused clustered regularly interspaced short palindromic repeats knockout screen to identify genes that undergo alterations during the treatment of tumor cells with PARPis. Of about 3000 genes in the screen, our data revealed that mitochondrial pyruvate carrier 1 (MPC1) is an essential factor in desensitizing nonsmall cell lung cancer (NSCLC) lung cancer lines to PARP inhibition. In contrast to NSCLC lung cancer cells, triple‐negative breast cancer cells do not exhibit such desensitization following MPC1 loss and reprogram the tricarboxylic acid cycle and oxidative phosphorylation pathways to overcome PARPi treatment. Our findings unveil a previously unknown synergistic response between MPC1 loss and PARP inhibition in lung cancer cells.

Subjects

MeSH terms (MEDLINE)

Drug Resistance, NeoplasmLung NeoplasmsMonocarboxylic Acid TransportersPoly(ADP-ribose) Polymerase InhibitorsHumansCell Line, TumorClustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsMitochondriaMitochondrial Membrane Transport ProteinsPhthalazinesPiperazines

Author keywords

CRISPR screenDNA damage responseNSCLCPARP inhibitorbreast cancermetabolism

Substances

Mitochondrial Membrane Transport ProteinsMonocarboxylic Acid TransportersPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsMPC1 protein, human

Authors and institutions

  • Developmental Therapeutics Branch, NCI Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States.
  • Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA.
  • Protein Characterization Laboratory, Frederick National Laboratory for Cancer Research, Cancer Research Technology Program, Leidos Biomedical Research Inc., Frederick, Maryland, USA.
  • Surgical Oncology Program, NCI Center for Cancer Research, NCI, NIH., Bethesda, Maryland, United States.
  • CCR Collaborative Bioinformatics Resource (CCBR), Leidos Biomedical Research Inc., Frederick, Maryland, USA.
  • Institute of Lung Health and Immunity, Helmholtz Center, Munich, Germany.

ORCID profiles: Urbain Weyemi

Funding

  • Intramural NIH HHS
  • NCI NIH HHS
  • NCI center for cancer research
  • National Cancer Institute

Cite

APA

Furusawa, T., Cavero, R., Liu, Y., Li, H., Xu, X., Andresson, T., Reinhold, W., White, O., Boufraqech, M., Meyer, T. J., Hartmann, O., Diefenbacher, M. E., Pommier, Y., & Weyemi, U. (2024). Metabolism‐focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer. Molecular Carcinogenesis, 63(6), 1024-1037. https://doi.org/10.1002/mc.23705

Vancouver

Furusawa T, Cavero R, Liu Y, Li H, Xu X, Andresson T, et al. Metabolism‐focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer. Molecular Carcinogenesis. 2024;63(6):1024-1037. doi:10.1002/mc.23705

BibTeX
@article{Furusawa2024,
  author = {Furusawa, Takashi and Cavero, Renzo and Liu, Yue and Li, Haojian and Xu, Xia and Andresson, Thorkell and Reinhold, William and White, Olivia and Boufraqech, Myriem and Meyer, Thomas J and Hartmann, Oliver and Diefenbacher, Markus E and Pommier, Yves and Weyemi, Urbain},
  title = {Metabolism‐focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer},
  journal = {Molecular Carcinogenesis},
  year = {2024},
  volume = {63},
  number = {6},
  pages = {1024--1037},
  doi = {10.1002/mc.23705}
}
Start for free →